HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA.

Abstract
In the past few years, much effort has been devoted to show the single-target specificity of nongenotoxic, p53 reactivating compounds. However, the divergent biological responses induced by the different compounds, even in the same tumor cells, demand additional mechanistic insights, whose knowledge may lead to improved drug design or selection of the most potent drug combinations. To address the molecular mechanism underlying induction of mitotic arrest versus clinically more desirable apoptosis, we took advantage of two MDM2 antagonists, Nutlin-3 and RITA, which respectively produce these two outcomes. We show that, along with p53 reactivation, the proapoptotic p53-activator HIPK2 is degraded by MDM2 in Nutlin-3-treated cells, but activated by transiently reduced MDM2 levels in RITA-treated ones. Gain- and loss-of-function experiments revealed the functional significance of MDM2-mediated HIPK2 regulation in cell decision between mitotic arrest and apoptosis in both types of p53 reactivation. These data indicate that strategies of p53 reactivation by MDM2 inhibition should also take into consideration MDM2 targets other than p53, such as the apoptosis activator HIPK2.
AuthorsCinzia Rinaldo, Andrea Prodosmo, Francesca Siepi, Alice Moncada, Ada Sacchi, Galina Selivanova, Silvia Soddu
JournalCancer research (Cancer Res) Vol. 69 Issue 15 Pg. 6241-8 (Aug 01 2009) ISSN: 1538-7445 [Electronic] United States
PMID19638586 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Carrier Proteins
  • Furans
  • Imidazoles
  • NSC 652287
  • Piperazines
  • RNA, Messenger
  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • nutlin 3
  • MDM2 protein, human
  • Proto-Oncogene Proteins c-mdm2
  • HIPK2 protein, human
  • Protein Serine-Threonine Kinases
Topics
  • Apoptosis (drug effects, physiology)
  • Carrier Proteins (biosynthesis, genetics, metabolism)
  • Cell Line, Tumor
  • Furans (pharmacology)
  • HCT116 Cells
  • Humans
  • Imidazoles (pharmacology)
  • Mitosis (drug effects)
  • Piperazines (pharmacology)
  • Protein Serine-Threonine Kinases (biosynthesis, deficiency, genetics, metabolism)
  • Proto-Oncogene Proteins c-mdm2 (antagonists & inhibitors, metabolism)
  • RNA, Messenger (biosynthesis, genetics)
  • Tumor Suppressor Protein p53 (metabolism)
  • Up-Regulation (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: